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Abstract
Background: Healthcare professionals are often reluctant to deprescribe fall-risk-increasing drugs (FRIDs). Lack of knowledge
and skills form a significant barrier and furthermore, there is no consensus on which medications are considered as FRIDs
despite several systematic reviews. To support clinicians in the management of FRIDs and to facilitate the deprescribing
process, STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk) and a deprescribing
tool were developed by a European expert group.
Methods: STOPPFall was created by two facilitators based on evidence from recent meta-analyses and national fall prevention
guidelines in Europe. Twenty-four panellists chose their level of agreement on a Likert scale with the items in the STOPPFall
in three Delphi panel rounds. A threshold of 70% was selected for consensus a priori. The panellists were asked whether
some agents are more fall-risk-increasing than others within the same pharmacological class. In an additional questionnaire,
panellists were asked in which cases deprescribing of FRIDs should be considered and how it should be performed.
Results: The panellists agreed on 14 medication classes to be included in the STOPPFall. They were mostly psychotropic
medications. The panellists indicated 18 differences between pharmacological subclasses with regard to fall-risk-increasing
properties. Practical deprescribing guidance was developed for STOPPFall medication classes.
Conclusion: STOPPFall was created using an expert Delphi consensus process and combined with a practical deprescribing
tool designed to optimise medication review. The effectiveness of these tools in falls prevention should be further evaluated
in intervention studies.
Keywords: accidental falls, fall-risk-increasing drugs, deprescribing, aged, adverse effects, older people
Key Points
• There is no consensus on which medications are considered as fall-risk-increasing drugs despite several systematic reviews.
• STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk) was built through a Delphi
process.
• The STOPPFall is more comprehensive than most national falls prevention guideline listings.
• It can provide a first step towards harmonising the practice and guidelines on drug-related falls in Europe.
• The STOPPFall has been combined with a practical deprescribing tool designed to assist in clinical decision-making.
Introduction
Falls are the leading cause of injury and injury-related
mortality in older adults [1]. They often result from
interacting risks, and one of the prominent risk factors is
fall-risk-increasing drugs (FRIDs) use [2–4]. FRIDs use is
common, but healthcare professionals are often reluctant to
deprescribe FRID [5,6]. Furthermore, there is uncertainty
about the effectiveness of FRIDs deprescribing as a stand-
alone intervention in falls prevention [7,8]. Regarding gen-
eral medication reviews, Cameron et al . [8] concluded that
they may make little or no difference to the rate of falls or risk
of falling in a long-term care setting. A Cochrane review in
2012 reported withdrawal of psychotropics and prescribing-
modification programme for primary care physicians to
be effective among community-dwelling older adults [7].
However, three other included deprescribing trials had
negative results in falls prevention [7].
In general, falls prevention guidelines emphasise that
older adults at high risk of falling should be assessed for risk
factors, including medication use [9]. Therefore, identifying
FRIDs is important as it is the starting point for possible
FRID deprescribing as part of the multifactorial falls preven-
tion strategy [5]. However, current national falls prevention
guidelines in Europe vary considerably in which medications
they include as risk factors for falls and some of them have
not been updated during the past decade [10–17].
In recent decades, numerous systematic reviews and meta-
analyses have summarised the associations between several
medication classes and falls risk [2–4]. However, these efforts
have some limitations. Firstly, the studies are often limited to













medication classes and falls to have sufficient statistical power
[5]. Secondly, as most studies do not focus on investigating
individual treatment effects, more work is warranted to
facilitate personalised drug optimization.
Currently, several explicit prescribing tools including
STOPP/START (Screening Tool of Older Persons poten-
tially inappropriate Prescriptions/Screening Tool to Alert
doctors to Right Treatment), Beers criteria, FORTA (Fit
fOR The Aged)-list and TIME (Turkish Inappropriate
Medication use in the Elderly) are available to guide
professionals in appropriate mediation use [18–21]. These
drug-optimization strategies include some aspects of falls
prevention, as FRIDs are mostly labelled as potential
falls causative factors [18–20]. Although these tools are
not comprehensive in their FRIDs listing, their use in
intervention studies has been shown to reduce falls [22,23].
As the existing lists do not represent a complete and uniform
medication list to be avoided in older adults at risk of falls,
a deprescribing tool focusing on purely medication-related
falls may be expected to be more effective in falls prevention
than general prescribing tools [24]. However, such a tool
should be integrated within a multifactorial falls prevention
strategy to achieve the best prospects of success.
The European Geriatric Medicine Society (EuGMS) Task
and Finish Group on FRIDs described in their recent state-
ment paper generic steps for FRIDs withdrawal, from med-
ication review to symptom monitoring after deprescribing
[5]. To further support clinicians in FRIDs deprescribing,
our first aim was to create a comprehensive STOPPFall
(Screening Tool of Older Persons Prescriptions in older
adults with high fall risk) by Delphi consensus for use as a
screening tool. Furthermore, we explored possible differences
in fall-risk-increasing properties between pharmacological
subclasses to gain further insight into medication review.
Our second aim was to combine the STOPPFall with a
deprescribing tool with practical guidance to simplify and
structure FRIDs deprescribing. Thirdly, we aimed at creating
consensus to facilitate harmonisation of clinical management
of drug-related falls across Europe.
Methods
STOPPFall was built through a consensus effort, using
a modified Delphi technique. A principal investigator of
STOPP/START (D.O.’M.) permitted us to use the name
STOPPFall after finalising this project [18,25]. In an
additional questionnaire, we asked (i) when to consider
deprescribing STOPPFall medications and (ii) how to mon-
itor patients’ clinical status after deprescribing with a view
to developing a deprescribing tool. The internet-based ques-
tionnaires were undertaken remotely and anonymously. The
Medical Ethics Research Committee of Amsterdam UMC,
location AMC declared that the Medical Research Involving
Human Subjects Act did not apply to this study. Panellists
gave written informed consent during each questionnaire.
A summary of the methods is given below and detailed
description is provided in Appendix I.
European expert panel and International advisory
board
In total, 24 members EuGMS Task and Finish Group on
FRIDs and Special Interest Group (SIG) on Pharmacology
accepted the invitation to participate in the Delphi
process and to fill in an additional deprescribing tool ques-
tionnaire [5,26,27]. A non-European international advisory
board was established consisting of experts on geriatric
pharmacotherapy.
Initial STOPPFall
Two facilitators created an initial STOPPFall based on evi-
dence from the three recently published systematic reviews
and meta-analyses and eight national falls prevention guide-
lines in Europe [2–4,10–17]. International advisers were
consulted regarding the initial STOPPFall.
Delphi rounds
The panellists were asked to indicate to what extent they
agreed with the medication classes included in the initial
STOPPFall using a Likert scale. Also, the panellists were
asked to propose missing medication classes. Furthermore,
statements were created based on the answers obtained in
round 1 about risk differences between the pharmacological
subclasses. The panellists were asked to indicate to what
extent they agreed with the statements. If >70% of the
panellists agreed (strongly agree/agree) with the proposed
STOPPFall medication class or with the statements, this was
considered consensus.
Questionnaire to develop a deprescribing tool
The panellists were asked about components of the patient-
centred deprescribing process [28]. To develop the ques-
tionnaire, a Medline search was performed (Appendix II).
The identified key resources from the literature were men-
tioned as references, and the panellists were provided with
the option to propose resources. The panellists were asked
to indicate for every medication class whether a stepwise
withdrawal is needed and choose the possible strategy for
withdrawal. Furthermore, they were asked in which situa-
tions withdrawal should be performed and were requested
to indicate those symptoms patients should be monitored
for after deprescribing. Finally, panellists were asked to indi-
cate how follow-up checks should be arranged. Also, the
results were added to the general decision tree of the FRIDs
management separately for every medication class [5].
Results
Each Delphi round questionnaire was completed by 24
panellists from 13 European countries during 2019 and the









niversity user on 22 D
ecem
ber 2020
L.J. Seppala et al.














Table 1. Statements about possible risk differences within the pharmacological classes that reached consensus
Antipsychotics • Risk difference is related to variation in (i) sedative, (ii) anticholinergic and (iii) alpha-receptor properties
Opioids • Strong opioids are more fall-risk-increasing than weak opioids
Antidepressants • Tricyclic antidepressants (TCA’s) are more fall-risk-increasing than others
• Risk difference is related to the variation in (i) sedative effects, (ii) propensity to cause orthostatic
hypotension and (iii) anticholinergic activity
Anticholinergics • Medications with high anticholinergic activity are more fall-risk-increasing than weak anticholinergics
Antiepileptics • Older generation antiepileptics are more fall-risk-increasing than newer antiepileptics
• Risk difference is related to the variation in sedative effects
Diuretics • Loop diuretics are more fall-risk-increasing than other diuretics
Alpha-blockers for benign prostatic hyperplasia • Non-selective alpha-blockers are more fall-risk-increasing than selective
Antihistamines • First-generation antihistamines are more fall-risk-increasing than second-generation antihistamines
• Risk difference is related to variation in (i) sedative effects and (ii) anticholinergic activity
Medications for overactive bladder and urge
incontinence
• Risk difference is related to variation in anticholinergic activity
Oral hypoglycaemics • Oral hypoglycaemic agents that can cause hypoglycaemia, sulfonylureas, are more risk-increasing than
other agents
STOPPFall
Figure 1 shows the results of the distribution of level of agree-
ments, whether the medication classes should be included
in the STOPPFall. In total, 14 classes were included. Con-
sensus for inclusion was reached in round 1 for anticholin-
ergics, diuretics, alpha-blockers used as antihypertensives,
opioids, antidepressants, antipsychotics, antiepileptics, ben-
zodiazepines and benzodiazepine-related drugs (Figure 1).
Regarding the inclusion in the STOPPFall of centrally-acting
antihypertensives, alpha-blockers for prostate hyperplasia,
antihistamines and vasodilators used in cardiac diseases, con-
sensus was achieved in round 2 (Figure 1). Finally, in round
3, consensus was reached for inclusion in the STOPPFall of
medications for overactive bladder and urge incontinence
(Figure 1). For 17 medication classes, no consensus was
reached (Figure 1).
Statements regarding subclass differences
Supplementary Figure 1 shows the distribution of levels
of agreements concerning statements about risk differences
within the pharmacological classes (Appendix III). Consen-
sus was achieved for the 18 statements shown in Table 1.
Deprescribing tool
A summary of the deprescribing guidance for STOPPFall
items can be found in Table 2 and the detailed results and the
deprescribing decision trees in Appendix IV and Appendix
V. Also, the decision trees are available as online tools;
https://kik.amc.nl/falls/decision-tree/.
Table 1 provides an overview of particular cases where
withdrawal should be considered at fall-risk assessment.
Figure 2 shows the detailed results for this question for each
medication class.
Table 2 shows a summary of how to decide whether a
stepwise withdrawal is needed, and the whole spread of the
panel’s responses to this question is shown in Figure 3. The
most frequently chosen and proposed strategies for tapering
can be found in Appendix V. The adverse drug withdrawal
effects and recurrence of symptoms for which patients should
be monitored are summarised in Table 2.
The panel was divided in their views on how often and for
how long follow-up checks should be continued following
deprescribing (Appendix V). Additional key deprescribing
resources identified from the literature search or proposed
by panellists are provided in Appendix V.
Discussion
In this expert effort by the EuGMS Task and Finish Group
on FRIDs and SIG on Pharmacology, a consensus was
achieved for 14 medication classes to create a comprehensive
list of FRIDs, STOPPFall. Many of these were psychotrop-
ics, but several less well-established risk medications were
also identified. However, the role of numerous medica-
tion classes as FRIDs are to be further elucidated, since
no consensus was reached for 17 classes. Furthermore, the
panellists indicated several differences in fall-risk-increasing
properties between pharmacological subclasses, especially
for antipsychotics and antidepressants. The STOPPFall was
combined with a practical deprescribing tool to facilitate
optimal deprescribing.
This is the first European-wide effort to establish a consen-
sus on FRIDs in older adults. It is evident when comparing
the STOPPFall to national fall prevention guidelines, that
it is more comprehensive than most guideline listings. The
STOPPFall contains items such as alpha-blockers, centrally-
acting antihypertensives, antihistamines and anticholiner-
gics, which are not regularly included in guidelines. The
difference can be explained by the different methodologies
used to create these listings. Typically, FRIDs in national
guidelines are based purely on associations derived from
meta-analyses. As some guidelines have not been updated
in recent years, these listings rely on data from older meta-
analyses and are therefore often not up-to-date [12–15,17].
In contrast, we asked the panellists to comment also based
on their expertise in the field and clinical experience.









niversity user on 22 D
ecem
ber 2020
L.J. Seppala et al.
Table 2. Deprescribing guidance for STOPPFall items
Fall-risk assessment:
In which cases to consider
withdrawal?a
Is stepwise withdrawal needed?b Monitoring after deprescribingc
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Always -If no indication for prescribing
-If safer alternative available
-Fall incidence and change in
symptoms e.g. OH, blurred vision,
dizziness




-If daytime sedation, cognitive
impairment, or psychomotor
impairments
-In case of both indications: sleep and
anxiety disorder
In general needed -Monitor: anxiety, insomnia, agitation
-Consider monitoring: delirium,
seizures, confusion
Antipsychotics -If extrapyramidal or cardiac side
effects, sedation, signs of sedation,
dizziness, or blurred vision
-If given for BPSD or sleep disorder,
possibly if given for bipolar disorder




Opioids -If slow reactions, impaired balance, or
sedative symptoms
-If given for chronic pain, and
possibly if given for acute pain






Antidepressants -If hyponatremia, OH, dizziness,
sedative symptoms, or
tachycardia/arrhythmia
-If given for depression but depended
on symptom-free time and history of
symptoms or given for sleep disorder,
and possibly if given for neuropathic
pain or anxiety disorder
In general needed -Monitor: recurrence of depression,
anxiety, irritability and insomnia
-Consider monitoring: headache,
malaise, gastrointestinal symptoms
Antiepileptics -If ataxia, somnolence, impaired
balance, or possibly in case of dizziness
-If given for anxiety disorder or
neuropathic pain
Consider -Monitor: recurrence of seizures
-Consider monitoring: anxiety,
restlessness, insomnia, headache
Diuretics -If OH, hypotension, or electrolyte
disturbance and possibly if urinary
incontinence
-possibly if given for hypertension
Consider -Monitor: heart failure, hypertension,
signs of fluid retention
Alpha-blockers (AB) used as
antihypertensives
-If hypotension, OH, or dizziness Consider -Monitor: hypertension
-Consider monitoring: palpitations,
headache
AB for prostate hyperplasia -If hypotension, OH, or dizziness In general not needed -Monitor: return of symptoms
Centrally-acting antihypertensives -If hypotension, OH, or sedative
symptoms
Consider -Monitor: hypertension
Sedative antihistamines -If confusion, drowsiness, dizziness, or
blurred vision
-In case of all indications:
hypnotic/sedative, chronic itch,
allergic symptoms
Consider -Monitor: return of symptoms
-Consider monitoring: insomnia,
anxiety
Vasodilators used in cardiac diseases -If hypotension, OH, or dizziness Consider -Monitor: symptoms of Angina
Pectoris
Overactive bladder and incontinence
medications
-If dizziness, confusion, blurred vision,
drowsiness, or increased QT-interval
Consider -Monitor: return of symptoms
aThis column includes answer categories that were chosen by more than 70% of the experts. In addition, after word ‘possibly’ are indicated the categories that were
selected by 30–70% of the experts. b‘In general needed’ indicates that >70% of experts chose categories of yes or depending. ‘Consider’ indicates that 30–70% of
experts chose categories of yes or depending. ‘In general not needed’ indicates that <30% of experts chose categories of yes or depending. c‘Monitor’ refers to >70%
of the experts selecting these symptoms. ‘Consider monitoring’ refers to 30–70% of the experts selecting these symptoms. BPSD, behavioural and psychological
symptoms of dementia; OH, orthostatic hypotension.
the section of ‘drugs that predictably increase the risk of falls
in older people’ in STOPP/START so that in general, the
STOPPFall could be expected to be more suited for falls pre-
vention. In STOPP/START version 2, only benzodiazepines,
neuroleptics, vasodilators with persistent postural hypoten-













Figure 2. Panel’s answers to ‘in which cases should withdrawal be considered?’
Furthermore, a consensus was reached for 18 statements
concerning differences in the fall-risk-increasing properties
within pharmacological classes. The lack of knowledge of
the risk related to pharmacological subclasses and individual
agents was identified by the Task and Finish Group as a
gap in the current literature [5]. The panellists frequently
identified variation in sedative effects, anticholinergic
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Figure 3. Panel’s answers to ‘whether stepwise withdrawal is needed in general?’.
features causing differences in medication-related falls risk.
These differences emphasise the need for critically evaluating
the choice of individual agents when prescribing FRIDs.
Moreover, to gain further insights into these risk differences,
the evaluation of specific pharmacological agents should
be a key item in the future FRIDs research agenda. Such
studies will enable the identification of safer prescription
alternatives.
It has been reported that deprescribing can be performed
safely in older people [29]. However, despite the growing
evidence on falls as an adverse drug reaction, deprescribing
FRIDs is often difficult and infrequently performed [5].
To support healthcare professionals in their decision-
making, we developed a practical deprescribing tool,
including important components of the deprescribing
process [28]. This practical guide can help overcome current
reluctance in clinical practice by providing an up-to-date
and straightforward source of expert knowledge. However,
for successful implementation, national dissemination
of this tool among healthcare professionals is essential.
The Task and Finish Group members intend to take a
role in this spread of knowledge e.g. through national
conferences, seminars and webpages. A link to the online
decision trees is available at the Task and Finish Group
webpage [30]. Finally, patient-centred care has been found
to improve patient satisfaction, adherence, quality of life
and overall health outcomes [28]. Therefore, patients
should be engaged throughout the process and their
personalised needs and concerns should be taken into
account [28,31].
Future research and clinical implications
Since panellists could not reach consensus on 17 medication
classes regarding whether they should be classified as
FRIDs, it is apparent that more research is warranted in
the future. Firstly, only a few studies have investigated
falls risk related to several of these medication classes
to date. Secondly, considering the quality issues in the
published observational studies including medication
and falls ascertainment and controlling for confounding,
advocating better research quality is important. Another
explanation for lack of consensus could be heterogeneous
treatment effects due to different patient characteristics.
Disentangling a single drug effect in the context of drug–
drug interactions and drug–disease interactions is difficult,
given the multiple causes for a fall and high prevalence
of polypharmacy in older patients. Furthermore, it is
challenging to label these medication classes, such as beta-
blockers, as purely FRIDs as they have known benefits
regarding prevention of cardiovascular disease and symptom
improvement. Thus, investigating heterogeneous treatment
effects and attempts to identify the older persons at risk
of medication-related falls are necessary to gain improved
insight. Furthermore, assessing effect of dosages, combina-
tion therapies and drug–drug interactions on falls risk was
beyond the scope of this study and should be addressed in
the future.
The EuGMS supports the use of STOPPFall as a screen-
ing tool to identify FRIDs when performing a medication
review in older fallers. Also, in accordance with our position









niversity user on 22 D
ecem
ber 2020
L.J. Seppala et al.
of falls and a high risk of falling before prescribing STOPP-
Fall medications for older people [5]. Furthermore, the
deprescribing tool is not aimed to be used as a stand-alone
strategy to reduce fall incidents but should be implemented
in a multifactorial strategy to achieve the best chance of suc-
cess. Finally, general interventions focusing on minimising
polypharmacy are unlikely to be effective at patient-level in
falls prevention since the population attributable risk frac-
tion related to polypharmacy alone is low [32]. Therefore, in
falls clinics and falls prevention programmes, deprescribing
strategies targeting FRIDs like the STOPPFall are warranted.
However, in a general geriatric setting, specific deprescribing
tools for every geriatric syndrome are undesirable. Therefore,
we have teamed up with the STOPP/START tools, and the
STOPPFall results will be included in the draft criteria of the
anticipated STOPP/START version 3 to be further validated
by the STOPP/START panellists.
Limitations
There are several limitations to this study related to the
Delphi process and to the use of online surveys. Firstly, the
formulation of the questions by the facilitators might have
influenced the responses, and individual panellists might
have interpreted the questions somewhat differently, even
though the purpose of the study was described in detail
in the invitation letters. Secondly, no face-to-face meetings
were organised during the rounds due to lack of feasibility
and inclusion of panellists from the whole continent. Such
meetings could have utilised the expertise better, but in con-
trast, the anonymous process probably avoided domination
by the substantial number of panellists or by the strength
of individual personalities. In the future, the STOPPFall
should be updated to maintain constant review. Thirdly, the
evidence given for panellists was based on heterogeneous
observational studies that have typically quality issues such
as accounting for confounding by indication. However, the
panellists were asked to indicate their view also based on their
own experience and thus consider these issues. Fourthly, a
general standard of consensus measurement and an agree-
ment concerning the declaration of consensus in Delphi
studies do not exist to date, and various methods have
been used. Furthermore, we did not formally evaluate the
stability of the consensus reached when applying the Delphi
process. However, there was a strong consensus regarding the
medication classes that reached consensus in round 1. Due to
the strong consensus, we do not expect that these medication
classes would not have reached consensus in the following
rounds if re-evaluated. Moreover, the medication classes that
reached consensus in round 2 or 3 had almost reached
consensus in the previous rounds. Finally, the data regarding
deprescribing as a single intervention in falls prevention
is inconclusive to date. The effectiveness of the STOPP-
Fall and accompanying deprescribing tool should still be
evaluated in different settings including community and
nursing homes.
Conclusion
A new screening tool STOPPFall was created with a
consensus Delphi effort. The STOPPFall contains mainly
psychotropic medications, but also several other pharma-
cological classes were recognised as risk factors. Therefore,
the STOPPFall is more comprehensive than most national
falls prevention guideline listings and can help harmonise
the practice and guidelines on drug-related falls in Europe.
The STOPPFall has been combined with a practical
deprescribing tool designed to assist in clinical decision-
making and simplify FRIDs management, and thereby
optimise care. Furthermore, it is mandatory to promote
high-quality research in defining the effects of FRID and
identifying best strategies to promote greater awareness and
knowledge among healthcare professionals on this topic.
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